Alan brings venture capital and pharmaceutical executive experience, having held leadership roles at Delin Ventures, AstraZeneca, and several therapeutics companies.
Rosie is a partner at Delin Ventures and a physician in the NHS. She also holds board positions across several life sciences and therapeutics companies.
The financing was backed by Delin Ventures, AlbionVC, Playfair Capital and 11.2 Capital to support international growth and research programmes.
"We developed the uMed platform to help healthcare professionals more easily and efficiently run patient research and targeted care programmes at scale, improving outcomes for patients by mitigating care gaps and accelerating research. Our groundbreaking patient cohorts give researchers access to unique data and insights, accelerating development and access to new therapies, while dramatically reducing the cost of finding, engaging and collecting prospective data from patients."
Novalis LifeSciences led the Series B round, which will fund team expansion and platform commercialisation.
"Our mission as a company is to enable widespread patient access to life saving cell and gene therapies. One of the biggest obstacles to achieving this is cell and gene therapy manufacturing processes that are too expensive, too highly variable and too low throughput. Our team is focused on the urgent need to enhance the ability of cell and gene therapy developers, CDMOs and Academic Medical Centers to deliver these therapies to as many patients as possible as quickly as possible,"
The seed follow on round was led by NFX with participation from existing investors.
"We see NFX's investment in Collective as a major vote of confidence in our ability to solve the protection gap problem for tens of millions of independent workers across the UK and Europe."
The Cambridge-based semiconductor IP supplier raised the funds to scale its engineering and commercial teams in Asia and North America.
"What excites us about Agile Analog is the potential for scale. Every other analog IP supplier is restricted to selling a limited range of standard IP products. But because Agile Analog’s unique technology enables it to create the IP that the customer wants, it can satisfy a wider range of customer requirements, and integrate more functionality into a chip design. As a result, the company is not limited by the size of today’s analog IP market – Agile Analog’s addressable market is potentially as big as the analog chip market. That is a huge opportunity which OMERS Ventures is pleased to help Agile Analog explore."
